PsychedelicNewsBreaks

TuesdayMar 29, 2022 12:15 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (“MDD”). According to the update, data from the studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. “The completion of these in vivo preclinical studies for CYB003 represents a…

Continue Reading

FridayMar 25, 2022 10:58 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved a key milestone. The milestones were identified in the Dec. 4, 2020, contribution agreement between Cybin and Adelia and include Year 1 Q4 (vi), Year 2 Q2 (ii), Year 2 Q2 (v) and Year 2, Q3 (iii). Others involved in the agreement include Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. According to the agreement, Adelia shareholders will be issued 90,546.0 Class B shares in Cybin; those shares are exchangeable…

Continue Reading

ThursdayMar 24, 2022 2:12 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study will evaluate participants’ experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” Cybin’s Chief Executive Officer Doug Drysdale said in the press release. “Until now, our understanding of the psychedelic experience has been fairly subjective.…

Continue Reading

ThursdayMar 24, 2022 1:42 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has received conditional approval from the Institutional Review Board ("IRB") for its planned multisite phase 2b smoking cessation trial. According to the announcement, Johns Hopkins University will serve as the lead investigational site for the study. The company anticipates submitting its IND application in the second quarter, with hopes that the study will begin shortly thereafter. Calling the approval a “significant milestone,” the company noted that its mission is to provide safer, more effective solutions to address nicotine dependence…

Continue Reading

WednesdayMar 23, 2022 1:55 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Participating, Presenting at Upcoming Investor Conferences

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be represented at three upcoming events: the Scottsdale Capital Event, Planet MicroCap Showcase and H.C. Wainwright Annual Global Life Sciences Conference. Delic CEO and cofounder Matt Stang will present at each event, including providing an outline of the company’s strategic outlook; he  will also be available for one-on-one meetings at each event. Hosted by Capital Event Management, the Scottsdale Capital Event is scheduled for April 22–24, 2022. This event is designed to connect growing companies with premier financiers through meetings and…

Continue Reading

MondayMar 21, 2022 2:10 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently received its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. According to Cybin CEO Doug Drysdale, the patent adds strong protection to the company’s growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments it is making in its CYB004 program. “Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the…

Continue Reading

MondayMar 21, 2022 1:43 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Scalable Approach to Psychedelic-Based Treatments Aimed at ‘Giving People Their Best Selves Back’

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, aims to help people live better lives through the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC”). The chain operates in multiple locations, strategically located in secondary cities to improve accessibility and reach and serve the greatest number of patients. In addition, the company’s scientific backbone, DELIC Labs, is a federally authorized psilocybin and cannabis research laboratory that dedicates its efforts to improving extraction, analytical testing and chemical processes. The lab’s R&D solutions for product lines and new intellectual property (“IP”) serve as the engine…

Continue Reading

ThursdayMar 17, 2022 3:05 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Playing Pivotal Role in Renaissance of Psychedelics

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is among organizations, working alongside researchers at the center of the veritable renaissance of psychedelics. “Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first- and second-generation novel compounds for the treatment of mental health and addiction and sequentially collaborating with academics to undertake vital clinical research on them. So far, Mydecine has partnered with Johns Hopkins University to launch a clinical trial utilizing psilocybin for smoking cessation. Led…

Continue Reading

ThursdayMar 17, 2022 11:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO, Cofounder Featured on the Jesse Tee Show Interview

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and company CEO and cofounder Matt Stang were spotlighted during a recent segment of the Jesse Tee Show. During the interview, Stang provided a summary of the journey to his present position with Delic Holdings, noting that he started as an intern with “High Times.” He worked in several positions at the publication, eventually buying out one of the owners. Stang also discussed the therapeutic potential of psychedelic compounds and provided a brief history of Delic. “In 2016, we put ‘High Times’ up…

Continue Reading

WednesdayMar 16, 2022 11:30 am

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Footprint with Opening of Reno Clinic

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its presence within the state of Nevada with the opening of its Reno location. According to the announcement, KWC Reno is the second of the company's clinics to open in Nevada within the last 18 months, bringing the total number of KWC clinics to 13 across nine states. The 2,200-square-foot treatment facility will serve local patients while also opening its doors to patients in larger California markets who do not have access to affordable in-state providers. “With…

Continue Reading